title: [Alveolar hypoxemic interstitial pneumonia related to rituximab therapy].
abstract: BACKGROUND
  Rituximab is indicated for the treatment of low-grade lymphoma. Pulmonary toxicity related to rituximab is exceptional.
  
  
  METHODS
  Here we report a patient with non-Hodgkin lymphoma treated with "CHOP" chemotherapy (cyclophosphosphamide, adriamycin, vincristine and prednisolone) and rituximab who developed an interstitial pneumonia with acute respiratory failure. The differential diagnosis of this clinical and radiological diagnosis is discussed.
  
  
  CONCLUSIONS
  Although cases of interstitial pneumonia associated with rituximab are rare, they may be severe and thus any patient experiencing respiratory symptoms on this therapy should be monitored closely.
authors.affiliation: Service de Pneumologie, Hôpital Pasteur, CHU de Nice, France.
authors.forename: V
authors.initials: V
authors.lastname: Jullien
authors.forename: C
authors.initials: C
authors.lastname: Perrin
authors.forename: F
authors.initials: F
authors.lastname: Peyrade
authors.forename: F
authors.initials: F
authors.lastname: Lemoigne
authors.forename: R-M
authors.initials: RM
authors.lastname: Chichmanian
authors.forename: B
authors.initials: B
authors.lastname: Blaive
mesh_terms: D000208:Acute Disease; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001784:Blood Gas Analysis; D003131:Combined Modality Therapy; D003520:Cyclophosphamide; D003937:Diagnosis, Differential; D004317:Doxorubicin; D005260:Female; D006801:Humans; D000860:Hypoxia / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy; D010102:Oxygen Inhalation Therapy; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone; D011650:Pulmonary Alveoli; D012131:Respiratory Insufficiency / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014750:Vincristine
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone